Impact of Community Health Promoters: A Randomized Control Trial
Not Applicable
- Conditions
- Paediatricsmalaria, diarrhoea, respiratory infections, birth complications
- Registration Number
- PACTR201308000601715
- Lead Sponsor
- Jakob Svensson (IIES, Stockholm University)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other
- Sex
- All
- Target Recruitment
- 8000
Inclusion Criteria
All subjects living in a treatment villages can benefit from the presence of the CHP. However, for inclusion in the survey, a household must have at least one child under 5 years of age.
Exclusion Criteria
The exclusion criteria regarding the household surverys is the following: no children under 5 years of age.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Mortality for children under five
- Secondary Outcome Measures
Name Time Method Malaria morbidity in under 5 children;Diarrhoea morbidity in under 5 children;Acute Respiratory Infection morbidity in under 5 children;Percentage of malaria cases promptly treated with ACTs;Percentage of child diarrhoea cases promptly treated;Percentage of Acute Respiratory Infections (ARI) promptly treated;Percentage of children receiving Vitamin A supplementation (either through vitamin supplements or through fortified foods);Percentage of deliveries in a facility with trained medical help ;Percentage of first of antenatal care (ANC) visits within first four months of pregnancy ;Percentage of under-5 children sleeping under bed nets ;Percentage of households using treated or filtered water;Anthropometric indicators (height, weight, mid-upper arm circumference) for under 5 children;Haemoglobin level in under 5 children;Health knowledge
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the impact of community health promoters on malaria and diarrhoea in paediatric populations?
How does community health intervention compare to standard-of-care for respiratory infections and birth complications in low-resource settings?
Are there specific biomarkers associated with improved outcomes in community health promoter programs targeting paediatric diseases?
What adverse events are commonly reported in large-scale community health trials and how are they managed?
What combination strategies or alternative approaches exist for addressing malaria, diarrhoea, and respiratory infections in children compared to community health promoters?